Cardiothoracic & vascular anesthesia

Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients

JAMA SurgPublished Economic evaluation within the Fibrinogen Replenishment in Surgery (FIBERS) randomised trial

An erratum to this article was published (JAMA Surg, 1 Mar 2026 ↗)

Authors' conclusion

Fibrinogen concentrate is cost-effective when compared with cryoprecipitate in most bleeding adult patients who underwent cardiac surgery with acquired hypofibrinogenemia requiring fibrinogen replacement.

Study context

Population
Adults bleeding after cardiac surgery with acquired hypofibrinogenemia requiring fibrinogen replacement, 4 hospitals in Ontario, Canadasubset of FIBERS
Participants
495 adults
Comparison
Fibrinogen concentrate vs cryoprecipitate
Primary endpoint
Cost-effectiveness: ABP transfusion (7-day) and in-hospital resource utilization (28-day) costs; incremental net benefit
Follow-up
28 days
Methodological detailswithin-trial cost-effectiveness analysis, multicentre, net benefit regression, predefined subgroups, February 2017 to November 2018
  • Within-trial cost-effectiveness analysis
  • Multicentre
  • Net benefit regression
  • Predefined subgroups
  • February 2017 to November 2018

Primary result

As reported in the abstract

Total 28-day cost

Fibrinogen concentrate

CAD $38 180

Median · IQR CAD $26 350 [USD $19 622]-CAD $65 080 [USD $48 463]

Cryoprecipitate

CAD $38 790

Median · IQR CAD $26 180 [USD $19 495]-CAD $70 380 [USD $52 409]

Positive after excluding critically ill patients (11%); probability cost-effective 86% and 97% at $0 and CAD $2000 (USD $1489) willingness-to-pay

Further findings

Median CAD $

OutcomeFibrinogen concentrateCryoprecipitate
Total 7-day ABP cost2280 (IQR CAD $930 [USD $692]-CAD $4970 [USD $3701])2770 (IQR CAD $1140 [USD $849]-CAD $5000 [USD $3723])

Allogeneic blood product (ABP) transfusions

Similar in both treatment groups

Net benefit in nonelective and critically ill patients (subgroup)

Highly uncertain

Safety

Adverse events

Similar in both treatment groups

Original publication

Cost-effectiveness of Fibrinogen Concentrate vs Cryoprecipitate for Treating Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients. JAMA Surg. Published 1 March 2023. doi:10.1001/jamasurg.2022.6818

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.